Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 7/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CES2 | O00748 | 4/20 | 0.67 |
| ▸ | CES1 | P23141 | 4/20 | 0.67 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octanoic Acid SCHEMBL9128994 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL3769087 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Palmitic Acid SCHEMBL9127702 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Dodecanoate SCHEMBL9128358 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL3761890 | 1.00 | FABP3 (0.72) | FABP3CA1CES2CES1FFAR3 | |
| Palmitic Acid SCHEMBL1628227 | 0.97 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Myristic Acid SCHEMBL3765071 | 0.97 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Octanoic Acid SCHEMBL1316022 | 0.97 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL1360333 | 0.97 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 | |
| Stearic Acid SCHEMBL29620682 | 0.97 | FABP3 (0.75) | FABP3CA1CES2CES1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| US-20080050452-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-28 | — | — | US | disclosed |
| US-20080044491-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-21 | — | — | US | disclosed |
| US-20080014247-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| US-20080014278-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| WO-2008005705-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-01-10 | — | — | WO | disclosed |